ArticleThe Lancet. Rheumatology2021

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.

Paul C Cremer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.